RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Worth 30cNot so sure about that... Their cash position is dwarfing by at least 9-10M every quarter considering cash and cash equivalents final totals and cash raised during every quarter.
Operational cash flow is one thing, but there are other leaks.
SG&A went down significantly in Q3, so that's good.
The reason I doubt near term prospects is because intl revenues are dependant on product registration/ licences on top of GMP licences. So first you need GMP to be allowed to sell but then for each product, you need additionnal permissions for those products to end up on store shelves. This is the case for every intl deal except for Australia.
They might be announced independently or with first shipments announcements. But there haven't been news about succeeding to obtain product registrations yet. So, although management has been optimistic about making shipments in Q1 2021, there are no guarantees they will.